We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From Apr 2019 to Apr 2024
By Rory Gallivan
LONDON--AstraZeneca PLC (AZN.LN) Tuesday said the European Union has given full approval to its lung cancer treatment Tagrisso.
The European Commission has granted full marketing authorization for Tagrisso tablets for the treatment of adult patients with locally-advanced lung cancer, AstraZeneca said.
Shares at 1235 GMT, up 43 pence, or 0.9%, at 4,706 pence valuing the company at 59.55 billion pounds ($64.65 billion).
Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan
(END) Dow Jones Newswires
April 25, 2017 08:58 ET (12:58 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
